Workflow
国际医学(000516) - 2025 Q1 - 季度财报
000516IMIC(000516)2025-04-22 12:05

Financial Performance - The company's operating revenue for Q1 2025 was ¥997,091,245.37, a decrease of 14.99% compared to ¥1,172,923,244.52 in the same period last year[5]. - The net loss attributable to shareholders was ¥106,353,858.88, slightly worsening by 1.37% from a loss of ¥104,912,277.28 in the previous year[5]. - Total operating revenue for the current period was ¥997,091,245.37, a decrease of approximately 15% from ¥1,172,923,244.52 in the previous period[17]. - Net loss for the current period was ¥132,959,986.79, compared to a net loss of ¥131,877,100.92 in the previous period, indicating a slight increase in losses[18]. - Total comprehensive income for the period was -132,959,986.79, compared to -131,877,100.92 in the previous period, indicating a slight increase in losses[19]. - Basic and diluted earnings per share were both -0.0471, slightly worse than -0.0464 in the previous period[19]. Cash Flow - The net cash flow from operating activities increased by 11.20% to ¥243,804,159.36, compared to ¥219,246,919.94 in the same period last year[5]. - Net cash flow from operating activities was 243,804,159.36, an increase from 219,246,919.94 in the previous period[21]. - Cash inflow from operating activities totaled 1,076,605,731.63, down from 1,221,898,669.41 in the previous period[20]. - Cash outflow from operating activities was 832,801,572.27, compared to 1,002,651,749.47 in the previous period[21]. - Net cash flow from investing activities was -71,687,778.63, an improvement from -137,436,233.21 in the previous period[21]. - Cash inflow from financing activities was 99,980,000.00, down from 199,400,000.00 in the previous period[21]. - Net cash flow from financing activities was -351,075,002.20, worsening from -283,609,925.44 in the previous period[21]. - The ending cash and cash equivalents balance was 369,603,381.91, down from 742,163,400.11 in the previous period[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥10,318,842,882.85, down 2.98% from ¥10,636,321,992.89 at the end of the previous year[5]. - Total assets decreased to ¥10,318,842,882.85 from ¥10,636,321,992.89, a reduction of approximately 3%[15]. - Current liabilities totaled ¥4,075,263,256.04, down from ¥4,151,485,482.84, representing a decrease of about 2%[15]. - Non-current liabilities decreased to ¥2,904,549,572.58 from ¥3,012,846,469.03, a decline of approximately 4%[15]. - The company's total equity decreased to ¥3,339,030,054.23 from ¥3,471,990,041.02, indicating a decline of approximately 4%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 109,907, with the largest shareholder holding 27.25% of the shares[10]. Other Information - Non-recurring gains and losses amounted to ¥13,392,880.03, primarily from government subsidies and fair value changes of financial assets[6]. - The company reported a significant reduction in credit impairment losses by 423.78% compared to the previous year, indicating improved asset quality[8]. - The company has not disclosed any new product developments or market expansion strategies in this report[5]. - The company's weighted average return on equity was -2.94%, a decrease of 0.22% from -2.72% in the previous year[5]. - The company's cash and cash equivalents decreased to ¥471,603,381.91 from ¥590,562,003.38, a drop of about 20%[13]. - Accounts receivable decreased to ¥690,857,166.93 from ¥739,394,118.00, reflecting a decline of approximately 7%[13]. - Inventory decreased to ¥63,274,718.58 from ¥81,005,105.26, a reduction of about 22%[14]. - The company’s first quarter report was not audited[23].